期刊文献+

米卡芬净与两性霉素B脂质体治疗肾移植术后肺部真菌感染的临床对照研究 被引量:9

下载PDF
导出
摘要 目的评价和比较米卡芬净与两性霉素B脂质体在肾移植患者经验性抗真菌治疗的有效性和安全性。方法回顾性研究真菌感染的高危因素肾移植患者,入选患者分为两组,米卡芬净组静脉滴注米卡芬净(100mg,1次/d);两性霉素B脂质体组静脉滴注两性霉素B脂质体1~3mg/(kg.d)。两组治疗时间均持续至体温正常后5d或者疗程>10d。观察两组患者的疗效和不良反应。结果共有43例患者接受评估,米卡芬净组24例,总有效率66.7%,不良反应发生率为20.5%;两性霉素B脂质体组19例,总有效率84.2%,不良反应发生率为57.9%,米卡芬净组有效率低于两性霉素B组(P<0.05),但不良反应率显著低于脂质体两性霉素B组(P<0.05)。结论对肾移植术后患者的经验性抗真菌治疗,米卡芬净的疗效低于脂质体两性霉素B,但耐受性较两性霉素B脂质体好,在抗霉菌药物的选择上需个体化。
出处 《广东医学》 CAS CSCD 北大核心 2010年第4期510-513,共4页 Guangdong Medical Journal
  • 相关文献

参考文献9

  • 1WEILAND D, FERGUSON R M, PETERSON P K, et al. Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management [ J]. Ann Surg, 1983, 198(5) : 622 -629.
  • 2PAYA C V. Fungal infections in solid- organ transplantation[ J ]. Recent Results Cancer Res, 1988,108(4) : 61.
  • 3夏路风,李扬,傅得兴.棘白菌素类抗真菌药米卡芬净的药理与临床评价[J].中国新药杂志,2007,16(5):410-413. 被引量:19
  • 4ASCIOGLU S, REX J H, DE PAUW B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J]. Clin Infect Dis, 2002, 34( 1 ) : 7.
  • 5LIN S J, SCHRANZ J, TEUTSCH S M. Aspergillosis case - fatality rate: systematic review of literature[ J]. Clin Infect Dis, 2001, 32(3) : 358 -366.
  • 6郭宁如,吴绍熙.二性霉素B脂质体的研究与应用[J].中国新药杂志,1996,5(4):261-265. 被引量:8
  • 7殷凯生,王彤,廖万清,洪微,尹有宽,章婉琴,诸葛传德,许蓓.国产注射用两性霉素B脂质体治疗深部真菌病的疗效与安全性的临床研究[J].中华医院感染学杂志,2004,14(8):850-854. 被引量:34
  • 8IKEDA F. Anti fungal activity and clinical efficacy of micafungin (funguard)[J]. J Med Mycol, 2005, 46: 217.
  • 9CHANDRASEKAR P H, SOBEL J D. Micafungin: a new echinocandin[J]. Clin Infect Dis, 2006, 42(8): 1171-1178.

二级参考文献22

  • 1Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species[J]. Clin Infect Dis,1995, 20(6): 1526-1530.
  • 2Sharkey PK, Graybill JR, Johnson ES et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS[J]. Clin Infect Dis,1996, 22(2): 315-321.
  • 3Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients[J]. J Antimicrob Chemother, 2002, 49(Suppl S1): 81-86.
  • 4Press release:Fujisawa changes its expectation for approval tinimg of micafungin,a candin antifungal agent[C].US:Fujisawa Healthcare Inc,2003.
  • 5TOMISHIMA M,OHKI H,YAMADA A,et al.FK463,a novel water-soluble echinocandin lipopeptide:synthesis and antifungal activity[J].J Antibiot(Tokyo),1999,52(7):674 -676.
  • 6CHANDRASEKAR PH,SOBEL JD.Micafungin:a new echinochadin[J].Clin Infect Dis,2006,42 (8):1171-1178.
  • 7NISHIYAMA Y,UCHIDA K,YAMAGUCHI H.Morphological changes of Candida albicans induced by micafungin(FK463),a water-soluble echinocandin-like lipopeptide[J].J Electron Microsc,2005,51(1):247 -255.
  • 8TAWARA S,IKEDA F,MAKI K,et al.In vitro activities of a new lipopetide antigungal agent,FK463,against a variety of clinically important fungi[J].Antimicrob Agents Chemother,2000,44(1):57 -62.
  • 9MESSER SA,DIEKEMA DJ,BOKEN L,et al.Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp[J].J Clin Microbiol,2006,44(2):324 -326.
  • 10HIGASHIYAMA Y,KOHNO S.Micafungin:a therapeutic review[J].Expert Rev Anti Infect Ther,2004,2(3):345-355.

共引文献57

同被引文献83

引证文献9

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部